Literature DB >> 12392815

Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation.

Han Li1, Li Liu, Mary L David, Clark M Whitehead, Ming Chen, John R Fetter, Gerhard J Sperl, Rifat Pamukcu, W Joseph Thompson.   

Abstract

Exisulind and its analogues are inhibitors of cyclic GMP phosphodiesterases (PDEs) that have been shown to activate and induce protein kinase G, resulting in the induction of apoptosis in colon cancer cells. These drugs also reduce beta-catenin protein levels and decrease cyclin D1 mRNA levels in SW480 cells. Herein we report on studies pertaining to exisulind regulation of beta-catenin levels and activity in colon tumor cells. Exisulind and its higher-affinity PDE analogues, (Z)-5-fluoro-2-methyl-(4-pyridylidene)-3-(N-benzyl)-indenylacetamide hydrochloride (CP461) and (Z)-1H-indene-3-acetamide, 5-fluoro-2-methyl-N-(phenylmethyl)-1-[(3,4,5-trimethoxyphenyl)methylene] (CP248), reduced beta-catenin, including the nuclear beta-catenin in SW480 cells (EC(50) approximately 200 microM, 1 microM, and <1 microM, respectively). The 50% reduction of beta-catenin was seen in 8-14 hr. There was no change in beta-catenin mRNA. Exisulind-induced beta-catenin reduction was blocked by the proteasomal inhibitor MG132 (Z-leu-Leu-Leu-CHO), indicating that the effect of exisulind involved ubiquitin-proteasomal degradation. A consequence of reduced beta-catenin in SW480 cells was that exisulind, CP461, and CP248 caused a concentration- and time-dependent decrease in cyclin D1 levels (EC(50) approximately 300 microM, 1 microM, and <1 microM, respectively) in 4 hr. The effect was via decreased cyclin D1 mRNA levels. Exisulind-induced degradation of beta-catenin was not blocked by the inhibition of caspase-3 activity and/or apoptosis, and some SW480 cells showed a reduction in beta-catenin levels before the appearance of early apoptosis indicators. Expression of the N-terminal 170 amino acid fragment of beta-catenin reduced the effects of beta-catenin degradation, cyclin D1 reduction, and the apoptosis response to exisulind. These results indicate that exisulind-induced beta-catenin degradation precedes the induction of apoptosis and that the down-regulation of inappropriate beta-catenin-activated genes accounts in part for the pro-apoptotic effects of exisulind and CP461 in colon tumor cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12392815     DOI: 10.1016/s0006-2952(02)01345-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  20 in total

1.  Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling.

Authors:  Nan Li; Yaguang Xi; Heather N Tinsley; Evrim Gurpinar; Bernard D Gary; Bing Zhu; Yonghe Li; Xi Chen; Adam B Keeton; Ashraf H Abadi; Mary P Moyer; William E Grizzle; Wen-Chi Chang; Margie L Clapper; Gary A Piazza
Journal:  Mol Cancer Ther       Date:  2013-06-26       Impact factor: 6.261

2.  R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells.

Authors:  Jaideep Behari; Gang Zeng; Wade Otruba; Michael D Thompson; Peggy Muller; Amanda Micsenyi; Sandeep S Sekhon; Lorenzo Leoni; Satdarshan P S Monga
Journal:  J Hepatol       Date:  2006-12-21       Impact factor: 25.083

3.  A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity.

Authors:  Jason D Whitt; Nan Li; Heather N Tinsley; Xi Chen; Wei Zhang; Yonghe Li; Bernard D Gary; Adam B Keeton; Yaguang Xi; Ashraf H Abadi; William E Grizzle; Gary A Piazza
Journal:  Cancer Prev Res (Phila)       Date:  2012-05-03

4.  Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction.

Authors:  Anindita Das; David Durrant; Clint Mitchell; Eric Mayton; Nicholas N Hoke; Fadi N Salloum; Margaret A Park; Ian Qureshi; Ray Lee; Paul Dent; Rakesh C Kukreja
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-30       Impact factor: 11.205

Review 5.  Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome.

Authors:  G Martel; P Hamet; Johanne Tremblay
Journal:  Mol Cell Biochem       Date:  2009-11-25       Impact factor: 3.396

6.  A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.

Authors:  C L O'Bryant; C H Lieu; S Leong; R Boinpally; M Basche; L Gore; K Leonardi; M K Schultz; S Hariharan; L Chow; S Diab; A Gibbs; S G Eckhardt
Journal:  Cancer Chemother Pharmacol       Date:  2008-05-29       Impact factor: 3.333

7.  Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo.

Authors:  Xiao-Long Mei; Yang Yang; Yao-Jun Zhang; Yong Li; Jin-Ming Zhao; Jian-Ge Qiu; Wen-Ji Zhang; Qi-Wei Jiang; You-Qiu Xue; Di-Wei Zheng; Yao Chen; Wu-Ming Qin; Meng-Ning Wei; Zhi Shi
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

Review 8.  How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme.

Authors:  Mehdi Sanati; Samaneh Aminyavari; Hamid Mollazadeh; Bahram Bibak; Elmira Mohtashami; Amir R Afshari
Journal:  Pharmacol Rep       Date:  2022-01-20       Impact factor: 3.024

9.  Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants.

Authors:  Amit K Tiwari; Zhe-Sheng Chen
Journal:  Front Pharmacol       Date:  2013-06-25       Impact factor: 5.810

Review 10.  Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.

Authors:  Ariana A Entezari; Adam E Snook; Scott A Waldman
Journal:  Expert Opin Ther Targets       Date:  2021-06-15       Impact factor: 6.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.